Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.875
Bid: 6.50
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.75 (11.538%)
Open: 6.875
High: 6.875
Low: 6.875
Prev. Close: 6.875
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TSB Grant to Develop Dementia Diagnosis Products

13 Dec 2013 07:00

RNS Number : 4517V
IXICO plc
13 December 2013
 



 

IXICO Awarded Technology Strategy Board Grant to Support the Development of Dementia Diagnosis Products

 

13 December 2013, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that it has been awarded a Stratified Medicine Grant by the UK's innovation agency, the Technology Strategy Board to provide funding to support the development of products to address the global dementia challenge.

 

The grant has been awarded under the Technology Strategy Board's recently launched 'Advancing In-Vivo Imaging for Stratified Medicine' competition. 

 

For this project, a consortium led by IXICO, which includes Imperial College, London as a research partner, Medimmune Limited (the global biologics research and development arm of AstraZeneca) and a second leading global pharmaceutical company as commercial partners, will apply a machine learning framework to a unique combination of reference data to develop a digital dementia prognosis tool. This will use commonly collected diagnostic information (including MRI scans and cognitive, functional and demographic data) to stratify patients based on their expected rate of decline. This could help with the diagnosis of dementia in the clinic and also with the enrichment of patient populations enrolled in clinical trials of investigational drugs, potentially improving the likelihood of measuring a therapeutic effect.

 

Several further global pharmaceutical companies have expressed interest joining the project as collaborators, and contributing clinical trial data in due course. The total value of the 24 month research project is approximately £1 million. The value of the grant is £633,962 of which £456,956 is allocated to IXICO and the remainder to Imperial College. The pharmaceutical partners and collaborators are contributing scientific resources from their R&D teams and access to data from completed clinical trials.

 

This brings the total grant funding secured by IXICO in the last 18 months to approximately £2.6 million of which approximately £2.4 million remains to be drawn down by IXICO.

 

This week the Technology Strategy Board features IXICO, the "Dementia Champions", as its Success Story www.innovateuk.org/success-stories detailing a funding story that stretches back 5 years.

 

Professor Derek Hill, Chief Executive of IXICO commented: "We are pleased to have been awarded this Technology Strategy Board grant. IXICO's products and services are focused on three overlapping areas within clinical trials, experimental medicine and diagnostics; the scope of this project will benefit our work in each. We look forward to working with Imperial and our commercial collaborators to develop important tools with the potential to improve clinical diagnosis of dementia and accelerate the development of effective treatments for Alzheimer's disease."

 

 

Enquiries

 

IXICO plc

+44 207 691 2064

Derek Hill, CEO

Charles Spicer, VP Corporate Development

 

Peel Hunt LLP (Nominated Adviser and broker)

+44 207 418 8900

James Steel

Vijay Barathan

Harry Florry

 

FTI Consulting Limited (U.K. Investor Relations)

+44 207 831 3113

John Dineen

Simon Conway

 

 

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and being readied for launch into the wider clinical diagnostic market. Since incorporation, IXICO has been contracted by seven of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

 

About the Technology Strategy Board

The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMMMZZZRGFZZ
Date   Source Headline
15th Jan 200712:52 pmRNSAnnual Information Update
10th Jan 20073:32 pmRNSDirector/PDMR Shareholding
10th Jan 20073:31 pmRNSDirector/PDMR Shareholding
9th Jan 200710:15 amRNSBoard Changes
19th Dec 200612:43 pmRNSTotal Voting Rights
10th Nov 20061:03 pmRNSDirector/PDMR Shareholding
8th Nov 20067:01 amRNSFinal Results
1st Nov 200612:58 pmRNSBlocklisting Interim Review
27th Oct 20063:02 pmRNSNotice of Results
18th Sep 20062:36 pmRNSBlocklisting Interim Review
5th Sep 20067:01 amRNSBoard Changes
21st Jul 20067:00 amRNSBoard Appointment
5th Jun 20067:00 amRNSAppointment of Non-Exec
19th May 20069:38 amRNSHolding(s) in Company
11th May 200610:37 amRNSDirector/PDMR Shareholding
11th May 200610:35 amRNSDirector/PDMR Shareholding
8th May 20067:02 amRNSInterim Results
3rd May 200612:32 pmRNSBlocklisting Interim Review
27th Apr 200611:33 amRNSHolding(s) in Company
27th Apr 200611:22 amRNSHolding(s) in Company
26th Apr 20067:01 amRNSAdvisor Appointment
24th Apr 20067:01 amRNSProduct Launch
10th Apr 20067:01 amRNSResearch Update
30th Mar 200611:47 amRNSNotice of Results
17th Mar 20068:53 amRNSBlocklisting Interim Review
30th Jan 20064:41 pmRNSSecond Price Monitoring Extn
30th Jan 20064:40 pmRNSPrice Monitoring Extension
24th Jan 20062:40 pmRNSResult of AGM
9th Jan 20067:01 amRNSRe: Agreement
4th Jan 20061:20 pmRNSHolding(s) in Company
15th Dec 200511:32 amRNSDirector/PDMR Shareholding
30th Nov 20053:30 pmRNSBoard Change
28th Nov 20053:03 pmRNSResearch Update
15th Nov 20057:02 amRNSResearch Update
4th Nov 200512:50 pmRNSDirector/PDMR Shareholding
4th Nov 200512:47 pmRNSDirector/PDMR Shareholding
4th Nov 200512:45 pmRNSBlocklisting Interim Review
4th Nov 200512:15 pmRNSBoard Change
2nd Nov 20057:00 amRNSFinal Results
30th Sep 20057:01 amRNSResearch Update
28th Sep 20052:19 pmRNSNotice of Results
23rd Sep 20052:09 pmRNSBlocklisting Interim Review
30th Jun 200510:38 amRNSHolding(s) in Company
23rd Jun 20057:02 amRNSChange of Broker
16th Jun 20055:26 pmRNSBlocklisting Interim Review
16th May 20057:00 amRNSHolding(s) in Company
13th May 20051:59 pmRNSHolding(s) in Company
12th May 20055:10 pmRNSDirector Shareholding
12th May 20055:06 pmRNSDirector Shareholding
12th May 20054:59 pmRNSDirector Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.